BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Awrich AE, Stackhouse WJ, Cantrell JE, Patterson JH, Rudman D. Hyperdibasicaminoaciduria, hyperammonemia, and growth retardation: Treatment with arginine, lysine, and citrulline. J Pediatr 1975;87:731-8. [PMID: 1185337 DOI: 10.1016/s0022-3476(75)80296-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Hashmi SB, Ahmed S. Children with lysinuric protein intolerance: Experience from a lower middle income country. World J Clin Pediatr 2022; 11(4): 369-374 [DOI: 10.5409/wjcp.v11.i4.369] [Reference Citation Analysis]
2 Stroup BM, Marom R, Li X, Hsu CW, Chang CY, Truong LD, Dawson B, Grafe I, Chen Y, Jiang MM, Lanza D, Green JR, Sun Q, Barrish JP, Ani S, Christiansen AE, Seavitt JR, Dickinson ME, Kheradmand F, Heaney JD, Lee B, Burrage LC. A global Slc7a7 knockout mouse model demonstrates characteristic phenotypes of human lysinuric protein intolerance. Hum Mol Genet 2020;29:2171-84. [PMID: 32504080 DOI: 10.1093/hmg/ddaa107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 Pinto A, Ashmore C, Batzios S, Daly A, Dawson C, Dixon M, Evans S, Green D, Gribben J, Hunjan I, Jameson E, Newby C, Pierre G, Rajwal S, Robertson L, Santra S, Sharrard M, Vara R, White L, Wilcox G, Yilmaz O, MacDonald A. Dietary Management, Clinical Status and Outcome of Patients with Citrin Deficiency in the UK. Nutrients 2020;12:E3313. [PMID: 33137944 DOI: 10.3390/nu12113313] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
4 Alqarajeh F, Omorodion J, Bosfield K, Shur N, Ferreira CR. Lysinuric protein intolerance: Pearls to detect this otherwise easily missed diagnosis. Transl Sci Rare Dis 2020;5:81-6. [PMID: 33134088 DOI: 10.3233/TRD-190035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
5 Zhang E, Hou X, Yang H, Zou Y, Ju P. A novel bicoumarin-based multifunctional fluorescent probe for naked-eye sensing of amines/ammonia. Anal Methods 2020;12:1744-51. [DOI: 10.1039/d0ay00297f] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kärki M, Näntö-Salonen K, Niinikoski H, Tanner LM. Urine Beta2-Microglobulin Is an Early Marker of Renal Involvement in LPI. JIMD Rep 2016;25:47-55. [PMID: 26122628 DOI: 10.1007/8904_2015_465] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
7 Evelina M, Grazia M, Francesca O, Marta C, Paolo C, Rossella G, Franco A, Andrea B. Growth Hormone Deficiency and Lysinuric Protein Intolerance: Case Report and Review of the Literature. JIMD Rep 2015;19:35-41. [PMID: 25614305 DOI: 10.1007/8904_2014_362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
8 van Vliet D, Derks TG, van Rijn M, de Groot MJ, MacDonald A, Heiner-Fokkema MR, van Spronsen FJ. Single amino acid supplementation in aminoacidopathies: a systematic review. Orphanet J Rare Dis 2014;9:7. [PMID: 24422943 DOI: 10.1186/1750-1172-9-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
9 Niinikoski H, Lapatto R, Nuutinen M, Tanner L, Simell O, Näntö-Salonen K. Growth hormone therapy is safe and effective in patients with lysinuric protein intolerance. JIMD Rep 2011;1:43-7. [PMID: 23430827 DOI: 10.1007/8904_2011_15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
10 Saheki T, Kobayashi K, Terashi M, Ohura T, Yanagawa Y, Okano Y, Hattori T, Fujimoto H, Mutoh K, Kizaki Z, Inui A. Reduced carbohydrate intake in citrin-deficient subjects. J Inherit Metab Dis 2008;31:386-94. [PMID: 18415701 DOI: 10.1007/s10545-008-0752-x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
11 Esposito V, Lettiero T, Fecarotta S, Sebastio G, Parenti G, Salerno M. Growth hormone deficiency in a patient with lysinuric protein intolerance. Eur J Pediatr 2006;165:763-6. [PMID: 16775724 DOI: 10.1007/s00431-006-0170-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
12 Chillarón J, Bertran J, Palacín M. Heteromeric amino acid transporters: cystinuria and lysinuric protein intolerance. Membrane Transporter Diseases 2003. [DOI: 10.1007/978-1-4419-9023-5_14] [Reference Citation Analysis]
13 Simell O. Lysinuric Protein Intolerance. Inborn Metabolic Diseases 1990. [DOI: 10.1007/978-3-662-02613-7_44] [Reference Citation Analysis]
14 Goto I, Yoshimura T, Kuroiwa Y. Growth hormone studies in lysinuric protein intolerance. Eur J Pediatr 1984;141:240-2. [PMID: 6428892 DOI: 10.1007/BF00572769] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
15 Rajantie J, Simell O, Perheentupa J. "Basolateral" and mitochondrial membrane transport defect in the hepatocytes in lysinuric protein intolerance. Acta Paediatr Scand 1983;72:65-70. [PMID: 6407277 DOI: 10.1111/j.1651-2227.1983.tb09665.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.4] [Reference Citation Analysis]
16 Rajantie J, Simell O, Perheentupa J. Lysinuric protein intolerance. Basolateral transport defect in renal tubuli. J Clin Invest 1981;67:1078-82. [PMID: 7204568 DOI: 10.1172/jci110120] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 1.2] [Reference Citation Analysis]
17 Rajantie J, Simell O, Perheentupa J, Siimes MA. Changes in peripheral blood cells and serum ferritin in lysinuric protein intolerance. Acta Paediatr Scand 1980;69:741-5. [PMID: 6782826 DOI: 10.1111/j.1651-2227.1980.tb07143.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.3] [Reference Citation Analysis]
18 Rajantie J, Simell O, Perheentupa J. Intestinal absorption in lysinuric protein intolerance: impaired for diamino acids, normal for citrulline. Gut 1980;21:519-24. [PMID: 6776014 DOI: 10.1136/gut.21.6.519] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 0.7] [Reference Citation Analysis]
19 Desjeux JF, Simell RO, Dumontier AM, Perheentupa J. Lysine fluxes across the jejunal epithelium in lysinuric protein intolerance. J Clin Invest 1980;65:1382-7. [PMID: 6773985 DOI: 10.1172/JCI109802] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 1.2] [Reference Citation Analysis]
20 Herman RH, Cohn RM. The Biochemical Basis of Disease. Principles of Metabolic Control in Mammalian Systems 1980. [DOI: 10.1007/978-1-4613-3006-6_15] [Reference Citation Analysis]
21 Endres W, Zoulek G, Schaub J. Hyperdibasicaminoaciduria in a Turkish infant without evident protein intolerance. Eur J Pediatr 1979;131:33-41. [PMID: 436855 DOI: 10.1007/BF00442783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]